Metabolon Logo
Metabolon Logo

Scientists are increasingly using metabolomics together with other omics tools to better inform and enable critical decision-making across the various phases of the drug discovery and development process.

Experts will discuss how the integration of metabolomics with other omics data streams enables R&D programs to:

  • Support target identification, mechanism of action and biomarker discovery
  • Evaluate pharmacokinetics / pharmacodynamics relationships for design of optimal dosing strategy
  • Understand the heterogeneity of patient populations
  • Understand disease progression and drug efficacy
  • Inform on potential drug repurposing

Subject Matter Experts:

  • Luca A Lotta, MD, Ph.D., Vice President and Head, Cardiovascular Metabolic and Musculoskeletal Therapeutic Area Genetics, Regeneron Genetics Center (RGC), Regeneron Pharmaceuticals Inc. in New York (USA)
  • Richard Beger, Ph.D., Branch Chief, Omics, Modeling, Imaging and Chemistry (OMIC) Branch, NCTR, FDA
  • Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer, Metabolon